TP53 and hepatocellular carcinoma: Wang found that HCC patients with TP53 mutation were significantly correlated with high TMB (P = 0.0005) and exhibited poor prognosis (OS: HR = 1.58, P = 0.0109) [40], indicating that HCC patients with TP53 mutation were more likely to benefit from immune treatment.